Publications by authors named "H Kaimakliotis"
Purpose: UGN-101, a reverse thermal mitomycin gel for upper tract instillation, recently became the first FDA approved treatment for upper tract urothelial carcinoma (UTUC). However, the durability of UGN-101 treatment has not been well described. Here we present long term outcomes from our multi-institutional cohort for patients who initially responded to treatment.
View Article and Find Full Text PDFPurpose: To evaluate long-term outcomes of primary chemoablation using a mitomycin reverse thermal gel (UGN-101) in patients with low-grade upper tract urothelial carcinoma.
Materials And Methods: Patients who participated in the OLYMPUS trial (TC-UT-03, NCT02793128) and achieved a complete response (CR) after 6-weekly doses of UGN-101 were followed up to 12 months after initial CR. Those with CR at study completion were eligible for long-term follow-up for up to 5 years or until disease recurrence, progression, or death.
Correctly identifying perturbed biological pathways is a critical step in uncovering basic disease mechanisms and developing much-needed therapeutic strategies. However, whether current tools are optimal for unbiased discovery of relevant pathways remains unclear. Here, we create "Benchmark" to critically evaluate existing tools and find that most function sub-optimally.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the effectiveness of nivolumab, an immunotherapy drug, used before and after surgery in patients with high-risk renal cell carcinoma compared to traditional surgery alone.
- It was a randomized phase 3 trial involving 819 patients across multiple sites in the US and Canada, who were assigned to either the nivolumab plus surgery group or surgery only group.
- The primary outcome measured was recurrence-free survival, with safety being assessed for all patients who started treatment, and the trial has been officially closed to new participants.
Article Synopsis
- * Recent updates to the NCCN Guidelines for Bladder Cancer reflect changes from the fifth edition of the WHO Classification of Tumours, ensuring alignment with new standards.
- * The guidelines also introduce new treatment options for NMIBC that doesn't respond to bacillus Calmette-Guérin (BCG) therapy and provide updated recommendations for systemic therapy targeting advanced or metastatic bladder cancer.